ASRGL1 strongly inhibits the development of hepatocellular carcinoma by inhibiting the formation of the cyclin B/CDK1 complex, ultimately leading to the failure of transition from the G2 to M phase of the cell cycle [38]. This evidence concerns the gene ASRGL1 and hepatocellular carcinoma.